Etonitazene Powder (10g) $350
Etonitazene Powder (25g) $600
Etonitazene Powder (50g) $800
Etonitazene Powder (100g) $1500
Etonitazene Powder (500g) $6800.
Etonitazene Powder (1kg) $12,000
Order above 1 kilos please contact us.
Supply ability: 1 tons
Buy Etonitazene Powder
Illicit production and sale of etonitazene has been limited. Identified on the Moscow illegal drug market in 1998, it was primarily smoked in laced cigarettes. A chemist at Morton Thiokol produced the compound and placed it in a nasal inhaler. The drug was produced in Russia in 1996 and sold as 'Chinese Dwarf'. The drug resulted in an unconfirmed number of deaths due to its uncertain potency. It appears to have a steep dose-response curve, and unpredictable pharmacokinetics especially when injected, in a similar manner to some other potent opioids such as dextromoramide, which may cause etonitazene to be especially hazardous when compared to opioids of similar potency such as fentanyl.
Further information: List of benzimidazole opioids
A number of analogues are known, with the only other well-known compound to come out of the original 1950s research being clonitazene, which is much weaker than etonitazene (around 3x morphine). More recently since around late 2018 a number of designer analogues have started to appear on illicit markets around the world, with the most prominent compounds being metonitazene, isotonitazene and etazene, though others have continued to appear.
Of these analogues, only etonitazene and clonitazene are explicitly listed under UN conventions and so are controlled throughout the world. The rest would only be illegal in countries such as the US, Australia and New Zealand that have laws equivalent to the Federal Analog Act. In the United States it is a Schedule I narcotic controlled substance with a DEA ACSCN of 9624 and a zero annual manufacturing quota as of 2013.
Etonitazene and its related opioid agonist benzimidazoles were discovered in the late 1950s, by a team of Swiss researchers working at the pharmaceutical firm CIBA (now Novartis). One of the first compounds investigated by the Swiss team was 1-(β-diethylaminoethyl)-2-benzylbenzimidazole, which was found to possess 10% of the analgesic activity of morphine when tested in rodent bioassays. This finding encouraged the group to begin a comprehensive systematic study of 2-benzylbenzimidazoles and to establish the structure-activity relationship of this new family of analgesics. Two general synthetic methods were developed for the preparation of these compounds.
The first method involved the condensation of o-phenylenediamine with phenylacetonitrile to form a 2-benzylbenzimidazole. The benzimidazole is then alkylated with the desired 1-chloro-2-dialkylaminoethane, forming the final product. This particular procedure was most useful for the preparation of benzimidazoles that lacked substituents on the benzene rings. A diagram of this method is displayed below.[
Built with Website Design Program